56 related articles for article (PubMed ID: 2827044)
21. Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.
Weir MR; Fagan T; Chrysant S; Flamenbaum W; Kaihlanen PM; Lueg M; Anzalone D
J Hum Hypertens; 1994 Jul; 8(7):531-7. PubMed ID: 7932518
[TBL] [Abstract][Full Text] [Related]
22. Effects of hydrochlorothiazide, diltiazem and enalapril on mononuclear cell sodium and magnesium levels in systemic hypertension.
Abraham AS; Brooks BA; Grafstein Y; Barchilon E; Nubani N; Eylath U; Shemesh O
Am J Cardiol; 1991 Nov; 68(13):1357-61. PubMed ID: 1951126
[TBL] [Abstract][Full Text] [Related]
23. Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).
Fouad FM; Tarazi RC; Bravo EL; Textor SC
Hypertension; 1984; 6(2 Pt 1):167-74. PubMed ID: 6327515
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of efficacy of the enalapril-hydrochlorothiazide combination by ambulatory blood pressure monitoring in essential hypertensive patients].
Oigman W; Spritzer N; Introcaso L; Santello JL
Arq Bras Cardiol; 1993 Feb; 60(2):123-7. PubMed ID: 8240048
[TBL] [Abstract][Full Text] [Related]
25. Contrasting renal haemodynamic responses to the angiotensin converting enzyme inhibitor enalapril and the beta-adrenergic antagonist metoprolol in essential hypertension.
O'Connor DT; Mosley CA; Cervenka J; Bernstein KN
J Hypertens Suppl; 1984 Dec; 2(2):S89-92. PubMed ID: 6100882
[TBL] [Abstract][Full Text] [Related]
26. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension.
Fagard R; Lijnen P; Pardaens K; Thijs L; Vinck W
J Hum Hypertens; 2001 Mar; 15(3):161-7. PubMed ID: 11317199
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ramipril and enalapril in patients with essential hypertension.
Ruddy MC; Mroczek WJ
Pharmacotherapy; 1993; 13(3):224-8. PubMed ID: 8321736
[TBL] [Abstract][Full Text] [Related]
28. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of enalapril combined with diltiazem ER in patients with stage 3-4 essential hypertension.
Gavras H; Chrysant SG; Niederman AL; Marbury TC; Goldstein R; Conradi E
Clin Exp Hypertens; 1998 Jan; 20(1):41-52. PubMed ID: 9507787
[TBL] [Abstract][Full Text] [Related]
30. Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension?
Wu RA; Kailasam MT; Cervenka JH; Parmer RJ; Kennedy BP; Ziegler MG; O'Connor DT
J Hypertens; 1994 Nov; 12(11):1243-7. PubMed ID: 7868871
[TBL] [Abstract][Full Text] [Related]
31. Renovascular hypertension: treatment with the oral angiotensin-converting enzyme inhibitor enalapril.
Jackson B; Murphy BF; Johnston CI; Kincaid-Smith P; Whitworth JA
Am J Nephrol; 1986; 6(3):182-6. PubMed ID: 3017107
[TBL] [Abstract][Full Text] [Related]
32. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
33. [Antihypertensive efficacy and tolerability of diltiazem and enalapril, alone or in combination. DESG. Diltiazem Enalapril Study Group].
Zannad F; Gosse P; Bernard-Fernier MF; de La Garoullaye A
Presse Med; 1994 Oct; 23(29):1335-8. PubMed ID: 7984540
[TBL] [Abstract][Full Text] [Related]
34. [24-hour ambulatory monitoring of blood pressure in patients with essential hypertension: the effectiveness of enalapril therapy].
Siegelová J; Fiser B; Dusek J
Vnitr Lek; 1996 Feb; 42(2):98-101. PubMed ID: 8686198
[TBL] [Abstract][Full Text] [Related]
35. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
[TBL] [Abstract][Full Text] [Related]
36. Patient compliance and angiotensin converting enzyme inhibitors in hypertension.
Juncos LI
J Cardiovasc Pharmacol; 1990; 15 Suppl 3():S22-5. PubMed ID: 1691414
[TBL] [Abstract][Full Text] [Related]
37. Experimental and clinical experience with the calcium antagonist diltiazem in hypertension.
Kiowski W; Linder L; Bühler FR
J Cardiovasc Pharmacol; 1989; 13 Suppl 1():S25-8. PubMed ID: 2468973
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment of hypertension with the calcium channel blocker diltiazem.
Klein W
Clin Cardiol; 1987 May; 10(5):358-60. PubMed ID: 3594947
[TBL] [Abstract][Full Text] [Related]
39. Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison.
Maclean D; Ramsay LE; Richardson PJ
Br J Clin Pharmacol; 1990 Aug; 30(2):203-11. PubMed ID: 2206783
[TBL] [Abstract][Full Text] [Related]
40. Comparative efficacy and safety of enalapril and sustained-release nifedipine in patients with mild to moderate hypertension. The Enalapril vs Nifedipine French Study Group.
Gueret P; Artigou JY; Benichou M; Berland J; Fressinaud P; Grollier G; Nguyen CD
Drugs; 1990; 39 Suppl 2():67-72. PubMed ID: 2188826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
